Seres Therapeutics (MCRB) Misses Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'
August 12, 2016 8:01 AM EDTFBR Capital maintained an Outperform rating on Seres Therapeutics (NASDAQ: MCRB), and cut the price target to $23.00 (from $43.00), following the company's recent sell-off.
Analyst Vernon Bernardino commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic... More
